S&P 500   3,109.77 (+0.20%)
DOW   27,861.59 (+0.34%)
QQQ   201.74 (+0.02%)
BABA   185.81 (+0.51%)
GE   11.59 (+0.52%)
ACB   2.72 (-12.82%)
F   8.89 (+1.95%)
PRI   130.62 (+0.13%)
BAC   33.13 (+0.88%)
DIS   149.25 (+1.60%)
S&P 500   3,109.77 (+0.20%)
DOW   27,861.59 (+0.34%)
QQQ   201.74 (+0.02%)
BABA   185.81 (+0.51%)
GE   11.59 (+0.52%)
ACB   2.72 (-12.82%)
F   8.89 (+1.95%)
PRI   130.62 (+0.13%)
BAC   33.13 (+0.88%)
DIS   149.25 (+1.60%)
S&P 500   3,109.77 (+0.20%)
DOW   27,861.59 (+0.34%)
QQQ   201.74 (+0.02%)
BABA   185.81 (+0.51%)
GE   11.59 (+0.52%)
ACB   2.72 (-12.82%)
F   8.89 (+1.95%)
PRI   130.62 (+0.13%)
BAC   33.13 (+0.88%)
DIS   149.25 (+1.60%)
S&P 500   3,109.77 (+0.20%)
DOW   27,861.59 (+0.34%)
QQQ   201.74 (+0.02%)
BABA   185.81 (+0.51%)
GE   11.59 (+0.52%)
ACB   2.72 (-12.82%)
F   8.89 (+1.95%)
PRI   130.62 (+0.13%)
BAC   33.13 (+0.88%)
DIS   149.25 (+1.60%)
Log in

Best Stocks Under $50.00 for 2019

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $50.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $50.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $50.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Switch logo

#1 - Switch

NYSE:SWCH
Stock Price: $15.91
Market Cap: $3.91 billion
P/E Ratio: 176.7
Dividend Yield: 0.74 %
Consensus Rating: Buy
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $15.40 (-3.2% Upside)
Switch, Inc., through its subsidiary, Switch, Ltd., provides colocation space and related services primarily to technology and digital media companies in the United States. It develops and operates data centers in Nevada and Michigan. The company also serves cloud and managed service providers, financial institutions, IT and software providers, government agencies, network and telecommunications providers, and others that conduct critical business on the Internet. Switch, Inc. was founded in 2000 and is headquartered in Las Vegas, Nevada.
CareDx logo

#2 - CareDx

NASDAQ:CDNA
Stock Price: $19.99
Market Cap: $856.78 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $47.40 (137.1% Upside)
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
LiveRamp logo

#3 - LiveRamp

NYSE:RAMP
Stock Price: $49.26
Market Cap: $3.24 billion
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $62.60 (27.1% Upside)
LiveRamp Holdings, Inc. provides identity and data connectivity for powering exceptional customer experiences. The company offers IdentityLink, an identity resolution platform that connects people, data, and devices across the physical and digital world, powering privacy-compliant, people-based marketing that allows consumers to better connect with the brands and products they love. It also provides AbiliTec, an offline PII resolution technology that gives platforms and the marketers they work with the ability to connect and update what they know about consumers, resolve PII data across enterprise databases and systems, and deliver a better customer experience. The company was formerly known as Acxiom Holdings, Inc. and changed its name to LiveRamp Holdings, Inc. in October 2018. LiveRamp Holdings, Inc. was founded in 1969 and is headquartered in San Francisco, California.
TapImmune logo

#4 - TapImmune

NASDAQ:MRKR
Stock Price: $2.90
Market Cap: $130.31 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.72 (269.5% Upside)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.
G1 Therapeutics logo

#5 - G1 Therapeutics

NASDAQ:GTHX
Stock Price: $22.98
Market Cap: $853.85 million
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $62.60 (172.4% Upside)
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
ChemoCentryx logo

#6 - ChemoCentryx

NASDAQ:CCXI
Stock Price: $8.09
Market Cap: $505.02 million
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.33 (126.6% Upside)
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. The company is also developing Avacopan for the treatment of patients with complement 3 glomerulopathy and hidradenitis suppurativa. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis. Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Viking Therapeutics logo

#7 - Viking Therapeutics

NASDAQ:VKTX
Stock Price: $7.25
Market Cap: $529.69 million
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.76 (158.8% Upside)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in preclinical stage for X-linked adrenoleukodystrophy. The company was founded in 2012 and is headquartered in San Diego, California.
Brigham Minerals logo

#8 - Brigham Minerals

NYSE:MNRL
Stock Price: $19.07
Market Cap: $968.69 million
Dividend Yield: 6.98 %
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $25.36 (33.0% Upside)
Brigham Minerals, Inc. owns and operates a portfolio of mineral and royalty interests in the continental United States. The company primarily holds mineral and royalty interests in the Permian Basin in West Texas and New Mexico; the SCOOP/STACK plays in the Anadarko Basin of Oklahoma; the Denver-Julesburg Basin in Colorado; and Wyoming and the Williston Basin in North Dakota. As of December 31, 2018, it had mineral and royalty interests in approximately 48,100 net mineral acres; and owned mineral and royalty interests in 3,355 gross productive horizontal wells, which consisted of 3,064 oil wells and 291 natural gas wells. The company also had proved undeveloped reserves of 6,923 thousand barrels of oil; 30,062 million cubic feet of natural gas; and 3,220 million barrels of natural gas liquids for a total of 15,153 thousand barrels of oil equivalent. Brigham Minerals, Inc. was founded in 2012 and is based in Austin, Texas.
Viper Energy Partners logo

#9 - Viper Energy Partners

NASDAQ:VNOM
Stock Price: $22.71
Market Cap: $3.02 billion
P/E Ratio: 21.0
Dividend Yield: 8.23 %
Consensus Rating: Buy
Ratings Breakdown: 16 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $39.56 (74.2% Upside)
Viper Energy Partners LP owns, acquires, and exploits oil and natural gas properties in North America. As of December 31, 2018, it had mineral interests in 14,841 net royalty acres in the Permian Basin and Eagle Ford Shale with estimated proved oil and natural gas reserves of 63,136 thousand barrels of crude oil equivalent. Viper Energy Partners GP LLC operates as the general partner of the company. The company was founded in 2013 and is based in Midland, Texas.
Century Communities logo

#10 - Century Communities

NYSE:CCS
Stock Price: $27.20
Market Cap: $878.67 million
P/E Ratio: 6.9
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $35.38 (30.1% Upside)
Century Communities, Inc. engages in the design, development, construction, marketing, and sale of single-family attached and detached homes in metropolitan areas in Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Nevada, North Carolina, Ohio, South Carolina, Tennessee, Texas, Utah, and Washington. It is also involved in the entitlement and development of the underlying land; and the provision of mortgage, title, and insurance services to its home buyers. The company sells homes through its sales representatives, as well as through independent real estate brokers. Century Communities, Inc. was founded in 2000 and is headquartered in Greenwood Village, Colorado.
SharpSpring logo

#11 - SharpSpring

NASDAQ:SHSP
Stock Price: $10.98
Market Cap: $116.65 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.33 (57.9% Upside)
SharpSpring, Inc. operates as a cloud-based marketing technology company worldwide. The company offers SharpSpring, a marketing automation solution for small and mid-size businesses. It markets and sells its products and services through sales teams and third party resellers. The company was formerly known as SMTP, Inc. and changed its name to SharpSpring, Inc. in December 2015. SharpSpring, Inc. was founded in 1998 and is headquartered in Gainesville, Florida.
Applied Genetic Technologies logo

#12 - Applied Genetic Technologies

NASDAQ:AGTC
Stock Price: $2.71
Market Cap: $52.83 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.42 (358.2% Upside)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
Galmed Pharmaceuticals logo

#13 - Galmed Pharmaceuticals

NASDAQ:GLMD
Stock Price: $4.42
Market Cap: $95.63 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $30.00 (578.7% Upside)
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
SCYNEXIS logo

#14 - SCYNEXIS

NASDAQ:SCYX
Stock Price: $1.11
Market Cap: $65.38 million
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $5.00 (350.5% Upside)
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Agile Therapeutics logo

#15 - Agile Therapeutics

NASDAQ:AGRX
Stock Price: $1.71
Market Cap: $104.96 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $4.20 (145.6% Upside)
Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Store Capital logo

#16 - Store Capital

NYSE:STOR
Stock Price: $40.18
Market Cap: $9.40 billion
P/E Ratio: 21.8
Dividend Yield: 3.50 %
Consensus Rating: Buy
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $37.14 (-7.6% Upside)
STORE Capital Corporation is an internally managed net-lease real estate investment trust, or REIT, that is the leader in the acquisition, investment and management of Single Tenant Operational Real Estate, which is its target market and the inspiration for its name. STORE Capital is one of the largest and fastest growing net-lease REITs and owns a large, well-diversified portfolio that consists of investments in 2,255 property locations, substantially all of which are profit centers, in 49 states.
Corbus Pharmaceuticals logo

#17 - Corbus Pharmaceuticals

NASDAQ:CRBP
Stock Price: $4.64
Market Cap: $287.15 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $26.50 (471.1% Upside)
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases. In addition, it has a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Joint logo

#18 - Joint

NASDAQ:JYNT
Stock Price: $18.61
Market Cap: $249.54 million
P/E Ratio: 465.3
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $26.60 (42.9% Upside)
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Vivint Solar logo

#19 - Vivint Solar

NYSE:VSLR
Stock Price: $6.82
Market Cap: $796.01 million
Consensus Rating: Buy
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $11.58 (70.0% Upside)
Vivint Solar, Inc. provides distributed solar energy primarily to residential customers in the United States. It owns and installs solar energy systems through long-term customer contracts. The company also sells photovoltaic installation products, as well as solar renewable energy certificates. As of December 31, 2018, it had an aggregate capacity of 1,060.9 megawatts covering approximately 154,600 homes. The company was formerly known as V Solar Holdings, Inc. and changed its name to Vivint Solar, Inc. in April 2014. Vivint Solar, Inc. was founded in 2011 and is headquartered in Lehi, Utah.
Tecnoglass logo

#20 - Tecnoglass

NASDAQ:TGLS
Stock Price: $7.93
Market Cap: $354.14 million
P/E Ratio: 9.3
Dividend Yield: 7.20 %
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.00 (26.1% Upside)
Tecnoglass Inc., through its subsidiaries, manufactures, supplies, and installs architectural glass, windows, and associated aluminum products for the commercial and residential construction industries in North, Central, and South America. The company offers low emissivity, laminated/thermo-laminated, thermo-acoustic, tempered, silk-screened, curved, and digital print glass products. It also produces, exports, imports, and markets aluminum products, including profiles, rods, bars, plates, tubes, and other hardware used in the manufacture of architectural glass settings, such as windows, doors, spatial separators, and similar products. In addition, the company provides floating facades, windows and doors, interior dividers and commercial display windows, hurricane-proof windows, and other products, such as awnings, structures, automatic doors, and other components of architectural systems. It markets and sells its products under the Tecnoglass, ES Windows, and Alutions brands through internal and independent sales representatives, as wells as directly to distributors. The company was founded in 1984 and is headquartered in Barranquilla, Colombia. Tecnoglass Inc. is a subsidiary of Energy Holding Corporation.

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel